Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1947 1
1949 1
1950 2
1951 2
1953 1
1954 2
1955 2
1956 2
1958 2
1959 1
1961 1
1962 1
1964 1
1965 1
1967 1
1969 4
1970 4
1971 8
1972 4
1973 2
1974 11
1976 3
1977 4
1978 3
1979 2
1980 10
1981 6
1982 5
1983 4
1984 3
1985 2
1986 1
1987 3
1988 3
1989 7
1990 3
1991 2
1992 3
1993 4
1994 3
1995 3
1997 7
1998 7
1999 3
2000 3
2001 6
2002 10
2003 6
2004 16
2005 14
2006 12
2007 7
2008 9
2009 13
2010 6
2011 3
2012 6
2013 5
2014 15
2015 19
2016 9
2017 5
2018 4
2019 6
2020 9
2021 9
2022 11
2023 12
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Tami-Beth
Page 1
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Nissen SE, et al. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
Review of gene therapies for age-related macular degeneration.
Khanani AM, Thomas MJ, Aziz AA, Weng CY, Danzig CJ, Yiu G, Kiss S, Waheed NK, Kaiser PK. Khanani AM, et al. Eye (Lond). 2022 Feb;36(2):303-311. doi: 10.1038/s41433-021-01842-1. Epub 2022 Jan 11. Eye (Lond). 2022. PMID: 35017696 Free PMC article. Review.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ; CIRT Investigators. Ridker PM, et al. N Engl J Med. 2019 Feb 21;380(8):752-762. doi: 10.1056/NEJMoa1809798. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415610 Free PMC article. Clinical Trial.
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.
Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London NJS, Mein L, Sheth VS, Wolfe JD, Singer MA, Danzig CJ. Khanani AM, et al. Eye (Lond). 2023 Dec;37(17):3574-3581. doi: 10.1038/s41433-023-02553-5. Epub 2023 May 12. Eye (Lond). 2023. PMID: 37173428 Free PMC article.
Lown-Ganong-Levine syndrome.
Douglas JE, Mandel WJ, Danzig R, Hayakawa H. Douglas JE, et al. Circulation. 1972 May;45(5):1143-4. doi: 10.1161/01.cir.45.5.1143. Circulation. 1972. PMID: 5020803 No abstract available.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Acromegaly.
Danzig J. Danzig J. BMJ. 2007 Oct 20;335(7624):824-5. doi: 10.1136/bmj.39253.602141.AD. BMJ. 2007. PMID: 17947788 Free PMC article. Review.
341 results